Novo-Nordisk A/S (NVO)
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| August 26, 2025 | $0.58 | 2025-08-18 | 2025-08-18 |
| April 8, 2025 | $1.14 | 2025-03-31 | 2025-03-31 |
| August 26, 2024 | $0.52 | 2024-08-16 | 2024-08-16 |
| April 2, 2024 | $0.93 | 2024-03-22 | 2024-03-25 |
| August 29, 2023 | $0.88 | 2023-08-18 | 2023-08-21 |
Dividends Summary
- Novo-Nordisk A/S has issued 33 dividend payments over the past 22 years
- The most recent dividend was paid 70 days ago, on August 26, 2025
- The highest dividend payed out to investors during this period was $3.10 per share
- The average dividend paid during this period was $0.95 per share.
Company News
Novo Nordisk is preparing to provide an investor update focusing on its weight loss treatments, with potential excitement around a more convenient treatment form.
Pfizer reported Q3 earnings beating analyst expectations, with declining Covid revenues and a strategic pivot towards obesity therapies. The company is focusing on growth through pipeline expansion and potential acquisitions in the weight-loss drug market.
A new American Heart Association initiative highlights the interconnected health of heart, kidney, and metabolic systems, revealing that 9 in 10 U.S. adults have at least one component of CKM syndrome, which increases risks of heart attack, stroke, and heart failure.
Pfizer filed a lawsuit against Metsera and Novo Nordisk in Delaware Court, alleging antitrust violations and breach of contract after Novo Nordisk made an unsolicited $9 billion acquisition proposal that could disrupt Pfizer's planned $4.9 billion acquisition of Metsera.
Novo Nordisk and Eli Lilly have both cut prices on their weight-loss drugs Wegovy and Zepbound, respectively, in an apparent price war to attract more customers.